Photo taken from: Oncology Brothers/X
Feb 14, 2024, 18:13
Liposomal Irinotecan now FDA Oncology approved for 1L metastatic Pancreatic Cancer based off NAPOLI3 – Oncology Brothers
Oncology Brothers made the following post on X:
“Liposomal Irinotecan now FDA Oncology approved for 1L metastatic Pancreatic Cancer based off NAPOLI3: NALIRIFOX vs. Gem/Abrax
- mOS 11.1mos Vs 9.2mos (HR: 0.83)
- Cross trial comparison, similar OS w/ FOLFIRINIOX
- Save liposomal for later lines?”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46